Correlation Between Innate Pharma and Mediantechn

Can any of the company-specific risk be diversified away by investing in both Innate Pharma and Mediantechn at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innate Pharma and Mediantechn into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Innate Pharma and Mediantechn, you can compare the effects of market volatilities on Innate Pharma and Mediantechn and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innate Pharma with a short position of Mediantechn. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innate Pharma and Mediantechn.

Diversification Opportunities for Innate Pharma and Mediantechn

0.71

Correlation Coefficient

Innate Pharma  Mediantechn

Poor diversification

The 3 months correlation between Innate and Mediantechn is 0.71. Overlapping area represents the amount of risk that can be diversified away by holding Innate Pharma and Mediantechn in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mediantechn and Innate Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innate Pharma are associated (or correlated) with Mediantechn. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mediantechn has no effect on the direction of Innate Pharma i.e., Innate Pharma and Mediantechn go up and down completely randomly.

Pair Corralation between Innate Pharma and Mediantechn

Assuming the 90 days trading horizon Innate Pharma is expected to under-perform the Mediantechn. But the stock apears to be less risky and, when comparing its historical volatility, Innate Pharma is 1.06 times less risky than Mediantechn. The stock trades about 0.0 of its potential returns per unit of risk. The Mediantechn is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  416.00  in Mediantechn on September 16, 2024 and sell it today you would lose (25.00) from holding Mediantechn or give up 6.01% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Innate Pharma  vs.  Mediantechn

Innate Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Mediantechn

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mediantechn has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Mediantechn is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Innate Pharma and Mediantechn

The main advantage of trading using opposite Innate Pharma and Mediantechn positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innate Pharma position performs unexpectedly, Mediantechn can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mediantechn will offset losses from the drop in Mediantechn's long position.

The idea behind Innate Pharma and Mediantechn pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.